Andrew J. Fromkin
CIK 1341896 · President & CEO · last filed 2026-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.24M
Companies
5
Total Filings
34
Lifetime Open-Market Net
-$8.42M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMVT | Director | 131,400 | $39.90 | $5.24M | -$8.56M | 12 | 2026-05-29 |
| Immunovant, Inc. (IMVTW) Delisted | Director | 24,700 | — | — | $0 | 2 | 2020-05-18 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | Director | — | — | — | $0 | 3 | 2016-01-14 |
| Radius Health, Inc. (RDUS) Delisted | President & CEO | — | $30.00 | — | $0 | 1 | 2013-11-18 |
| CLINICAL DATA INC (CLDA) Delisted | CEO, President | 0 | — | — | $137.0K | 11 | 2011-04-14 |
Recent Filings · Page 2 of 4
34 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-12-01 | IMVT | Notice (144) | −12,350 | -$483.3K | EDGAR |
| 2023-04-14 | IMVT | Grant (A) | +12,523 | $0 | EDGAR |
| 2022-08-19 | IMVT | Grant (A) | +21,059 | $0 | EDGAR |
| 2022-01-12 | IMVT | Grant (A) | +21,726 | $0 | EDGAR |
| 2021-08-11 | IMVT | Buy (P) | +5,500 | $43.5K | EDGAR |
| 2021-03-23 | IMVT | Grant (A) | +15,500 | $0 | EDGAR |
| 2020-05-18 | Immunovant, Inc. (IMVTW) Delisted | Grant (A) | +24,700 | $0 | EDGAR |
| 2019-12-20 | Immunovant, Inc. (IMVTW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-11-03 | — | Mixed | −16 | $0 | |
| 2016-01-14 | Tobira Therapeutics, Inc. (TBRA) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.